Journal of the Advanced Practitioner in Oncology

Understanding EGFR+ Lung Cancer Help your patients newly diagnosed with EGFR-positive NSCLC understand what comes next. This easy-to-read, 4-page guide explains biomarker testing, targeted and combination therapies, possible side effects, staying on schedule, and treatment costs. Through a patient's perspective, patients can learn how these issues can affect daily life and feel better prepared to talk with their care team. Learn More

Elizabeth Dennis: Welcome to What Advanced Practitioners Need to Know About Management Strategies in Advanced EGFR-Positive Non–Small Cell Lung Cancer, a JADPRO Virtual Roundtable. My name's Elizabeth Dennis, and I am a nurse practitioner at Texas Oncology–Baylor Dallas Sammons. Joining me today are two of my colleagues. Chaely Medley: Hi, my name is Chaely Medley. I'm a thoracic oncology nurse practitioner, and I work at the Novant Cancer Institute in Winston-Salem, North Carolina.

Elizabeth Dennis: Hi, and welcome to What Advanced Practitioners Need to Know About Management Strategies in Advanced EGFR-Positive Non–Small Cell Lung Cancer, a JADPRO Virtual Roundtable. My name is Elizabeth Dennis. I'm a nurse practitioner here at Texas Oncology, Baylor Dallas Sammons. Joining me today are two of my colleagues. Megan Van Volkenburg: Hi, I'm Megan Van Volkenburg. I am a hematology oncology physician assistant at Atrium Health Levine Cancer Institute in Charlotte, North Carolina.

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients. For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Kim Grazier: Welcome to this Virtual Roundtable and what advanced practitioners need to know about the diagnosis, management, and evolving treatment landscape of follicular lymphoma. My name is Kim Grazier and I'm a nurse practitioner at Advocate Health. Joining me today for this discussion are Susan Woodward, a nurse practitioner at Moffitt Cancer Center, and Allison Karabinos, a pharmacist and my colleague at Advocate Health. Thank you so much for joining me today.

Amy Goodrich: Hello, and welcome to JADPRO's roundtable discussion titled “A Case-Based Discussion of BTK Inhibition in CLL.” I'm Amy Goodrich. I'm a nurse practitioner at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland. Joining me are two of my colleagues, Jill Miller and Mollie Moran. Jill and Mollie, I'll let both of you introduce yourselves. Jill, why don't you go first? Jill Miller: Sure. I'm Jill Miller.

Posted Friday, July 7, 2023 Host: Wendy Vogel, MSN, FNP, AOCNP® Guests: Sandra Brackert, NP, and Kathleen Polson, NP Gastrointestinal stromal tumors (GISTs) are considered rare, yet they represent the most common sarcomas of the gastrointestinal tract. Sandra Brackert, NP, of UCLA Sarcoma Center, and Kathleen Polson, NP, of Dana-Farber Cancer Institute, speak with host Wendy Vogel, MSN, FNP, AOCNP®, on the effective management of patients with GIST who have progressed on multiple therapies.

Patricia Mangan: Welcome to this Roundtable discussion about early-stage multiple myeloma (MM) and the AP's role in managing these patients. My name is Patricia Mangan, and I'm a nurse practitioner at the Abramson Cancer Center of the University of Pennsylvania. Joining me today for this discussion are my two colleagues, Amy Pierre and Oxana Megherea. Amy is a senior clinical director of Flatiron Health and nurse practitioner at Memorial Sloan Kettering.